Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 13
2004 11
2005 7
2006 8
2007 6
2008 8
2009 11
2010 6
2011 10
2012 7
2013 4
2014 4
2015 8
2016 6
2017 6
2018 6
2019 5
2020 9
2021 9
2022 6
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Results by year

Filters applied: . Clear all
Page 1
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Okugawa S, Ikeda M, Kashiwabara K, Moritoyo T, Kohsaka T, Shimizu T, Hagiya H, Hasegawa K, Otsuka F, Miwa A, Kisimoto N, Mizoguchi A, Imamura A, Ikeuchi K, Tsutsumi T, Jubishi D, Hashimoto H, Okamoto K, Harada S, Inoue JI, Seto Y, Moriya K. Okugawa S, et al. Among authors: inoue ji. Int J Antimicrob Agents. 2023 Sep;62(3):106922. doi: 10.1016/j.ijantimicag.2023.106922. Epub 2023 Jul 8. Int J Antimicrob Agents. 2023. PMID: 37429450 Free article. Clinical Trial.
A New 1,2-Naphthoquinone Derivative with Anti-lung Cancer Activity.
Nakagawa R, Tateishi H, Radwan MO, Chinen T, Ciftci H, Iwamaru K, Baba N, Tominaga Y, Koga R, Toma T, Inoue JI, Umezawa K, Fujita M, Otsuka M. Nakagawa R, et al. Among authors: inoue ji. Chem Pharm Bull (Tokyo). 2022;70(7):477-482. doi: 10.1248/cpb.c21-01087. Chem Pharm Bull (Tokyo). 2022. PMID: 35786566 Free article.
Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.
Ikeda M, Okugawa S, Kashiwabara K, Moritoyo T, Kanno Y, Jubishi D, Hashimoto H, Okamoto K, Tsushima K, Uchida Y, Mitsumura T, Igari H, Tsutsumi T, Araoka H, Yatera K, Yamamoto Y, Nakamura Y, Otani A, Yamashita M, Wakimoto Y, Shinohara T, Adachi-Katayama M, Oyabu T, Kanematsu A, Harada S, Takeshita Y, Nakano Y, Miyazaki Y, Sakao S, Saito M, Ogura S, Yamasaki K, Kawasuji H, Hataji O, Inoue JI, Seto Y, Moriya K. Ikeda M, et al. Among authors: inoue ji. Int J Infect Dis. 2023 Mar;128:355-363. doi: 10.1016/j.ijid.2022.12.039. Epub 2023 Jan 4. Int J Infect Dis. 2023. PMID: 36610659 Free PMC article. Clinical Trial.
Discovery of New Potent anti-MERS CoV Fusion Inhibitors.
Kandeel M, Yamamoto M, Park BK, Al-Taher A, Watanabe A, Gohda J, Kawaguchi Y, Oh-Hashi K, Kwon HJ, Inoue JI. Kandeel M, et al. Among authors: inoue ji. Front Pharmacol. 2021 Jun 2;12:685161. doi: 10.3389/fphar.2021.685161. eCollection 2021. Front Pharmacol. 2021. PMID: 34149429 Free PMC article.
157 results